Drug profile · INN
linagliptin and metformin hydrochloride
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
linagliptin and metformin hydrochloride (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Drug details — linagliptin and metformin hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
linagliptin and metformin hydrochloride (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is linagliptin and metformin hydrochloride?
linagliptin and metformin hydrochloride (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for linagliptin and metformin hydrochloride?
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE is a marketed brand name for linagliptin and metformin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of linagliptin and metformin hydrochloride?
linagliptin and metformin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.